Compare PIPR & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIPR | XENE |
|---|---|---|
| Founded | 1895 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.3B |
| IPO Year | 2003 | 2014 |
| Metric | PIPR | XENE |
|---|---|---|
| Price | $79.97 | $55.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $91.38 | $68.55 |
| AVG Volume (30 Days) | 574.6K | ★ 791.7K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | ★ 54.49 | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $1,904,217,000.00 | $311,000.00 |
| Revenue This Year | $12.30 | N/A |
| Revenue Next Year | $13.55 | $2,496.48 |
| P/E Ratio | $87.52 | ★ N/A |
| Revenue Growth | ★ 24.33 | N/A |
| 52 Week Low | $72.48 | $28.19 |
| 52 Week High | $380.26 | $62.91 |
| Indicator | PIPR | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 24.55 | 48.05 |
| Support Level | $76.20 | $52.92 |
| Resistance Level | $93.06 | $56.66 |
| Average True Range (ATR) | 2.73 | 1.91 |
| MACD | 4.61 | -0.29 |
| Stochastic Oscillator | 31.59 | 42.12 |
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.